InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,648.40
(
1.01%
)
US TECH 100
19,050.40
(
1.19%
)
Dow Jones
41,563.08
(
0.55%
)
Brent Oil
77.20
(
0.01%
)
Bitcoin
59,326.53
(
0.35%
)
Post# of 253010
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120354
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dav1234 post# 143854

Thursday, 06/14/2012 11:31:45 AM

Thursday, June 14, 2012 11:31:45 AM

Post# of 253010
Teva’s thrice-weekly 40mg Copaxone will (if approved) be a distinct branded drug from regular Copaxone (which is dosed 20mg qD). Hence, thrice-weekly Copaxone will not be substitutable when a prescription is written for regular Copaxone.

Prescriptions written for thrice-weekly Copaxone could cannibalize sales of regular Copaxone to some degree if neuros actually think it a better product, but I would expect such cannibalization to be relatively small given the longstanding safety record of regular Copaxone.

p.s. Thrice-weekly Copaxone has no effect on the Copaxone patent litigation between Teva, NVS/MNTA, and MYL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up